Comparison between nonspecific and necrosis-avid gadolinium contrast agents in vascular disrupting agent-induced necrosis of rodent tumors at 3.0T

Investigative Radiology

Volumn 46, Issue 9, 2011, Pages 531-538

  Wang, Huaijun ^a   Miranda Cona, Marlein ^a   Chen, Feng ^a,b   Li, Junjie ^a   Yu, Jie ^a   Feng, Yuanbo ^a   Peeters, Ronald ^a   De Keyzer, Frederik ^a   Marchal, Guy ^a   Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

combretastatin A4 phosphate (CA4P); contrast agent; magnetic resonance imaging (MRI); necrosis avid contrast agent (NACA); tumor necrosis; vascular disrupting agent (VDA)

Indexed keywords

COMBRETASTATIN A4 PHOSPHATE; CONTRAST MEDIUM; EOSIN; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; HEMATOXYLIN; NECROSIS AVID CONTRAST AGENT; UNCLASSIFIED DRUG; VASCULAR TARGETING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DIFFUSION WEIGHTED IMAGING; HISTOPATHOLOGY; LIVER TUMOR; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; RHABDOMYOSARCOMA; STAINING; TUMOR NECROSIS;

EID: 80051726267     PISSN: 00209996     EISSN: 15360210     Source Type: Journal    
DOI: 10.1097/RLI.0b013e31821a2116     Document Type: Article

References (47)

1. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer. 2004;100:2491-2499. (Pubitemid 38715753)
2. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs. 2009;18:189-197.
3. Lippert JW III. Vascular disrupting agents. Bioorg Med Chem. 2007;15:605-615. (Pubitemid 44880701)
4. Wang H, Marchal G, Ni Y. Multiparametric MRI biomarkers for measuring vascular disrupting effect on cancer. World J Radiol. 2011;3:1-16.
5. Koukourakis MI, Mavanis I, Kouklakis G, et al. Early anti-vascular effects of bevacizumab anti-VEGF monoclonal antibody on colorectal carcinomas assessed with functional CT imaging. Am J Clin Oncol. 2007;30:315-318. (Pubitemid 46884155)
6. Bolondi L, Correas JM, Lencioni R, et al. New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. Dig Liver Dis. 2007;39:187-195. (Pubitemid 46117926)
7. Collins DJ, Padhani AR. Dynamic magnetic resonance imaging of tumor perfusion: approaches and biomedical challenges. IEEE Eng Med Biol Mag. 2004;23:65-83. (Pubitemid 39545969)
8. 215O-PET and DCE-MRI to measure tumor blood flow. Oncologist. 2008;13:631-644. (Pubitemid 351904908)
9. Pandharipande PV, Krinsky GA, Rusinek H, et al. Perfusion imaging of the liver: current challenges and future goals. Radiology. 2005;234:661-673. (Pubitemid 40250807)
10. Chen F, De Keyzer F, Wang H, et al. Diffusion weighted imaging in small rodents using clinical MRI scanners. Methods. 2007;43:12-20. (Pubitemid 47285730)
11. Padhani AR, Liu G, Mu-Koh D, et al. Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia. 2009;11:102-125.
12. Koh DM, Collins DJ. Diffusion-weighted MRI in the body: applications and challenges in oncology. Am J Roentgenol. 2007;188:1622-1635. (Pubitemid 46866868)
13. Thoeny HC, De Keyzer F, Chen F, et al. Diffusion-weighted MR imaging in monitoring the effect of a vascular targeting agent on rhabdomyosarcoma in rats. Radiology. 2005;234:756-764. (Pubitemid 40250819)
14. Takahara T, Kwee TC, Van Leeuwen MS, et al. Diffusion-weighted magnetic resonance imaging of the liver using tracking only navigator echo: feasibility study. Invest Radiol. 2010;45:57-63.
15. Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol. 2005;40:526-535. (Pubitemid 41040690)
16. Carlsson M, Arheden H, Higgins CB, et al. Magnetic resonance imaging as a potential gold standard for infarct quantification. J Electrocardiol. 2008;41:614-620.
17. Marcu CB, Nijveldt R, Beek AM, et al. Delayed contrast enhancement magnetic resonance imaging for the assessment of cardiac disease. Heart Lung Circ. 2007;16:70-78. (Pubitemid 46421764)
18. Aghi M, Gaviani P, Henson JW, et al. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005;11:8600-8605. (Pubitemid 43005906)
19. Wang H, Li J, Chen F, et al. Morphological, functional and metabolic imaging biomarkers: assessment of vascular-disrupting effect on rodent liver tumours. Eur Radiol. 2010;20:2013-2026.
20. Ni Y, Cresens E, Adriaens P, et al. Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol. 2002;9(Suppl 2):S488-S490. (Pubitemid 34857763)
21. Choi SI, Choi SH, Kim ST, et al. Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology. 2000;215:863-868. (Pubitemid 30346031)
22. Jin J, Teng G, Feng Y, et al. Magnetic resonance imaging of acute reperfused myocardial infarction: intraindividual comparison of ECIII-60 and Gd-DTPA in a swine model. Cardiovasc Intervent Radiol. 2007;30:248-256. (Pubitemid 46147116)
23. Ni Y, Chen F, Mulier S, et al. Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis-avid contrast agent. Eur Radiol. 2006;16:1031-1040.
24. Chen F, Sun X, De Keyzer F, et al. Liver tumor model with implanted rhabdomyosarcoma in rats: MR imaging, microangiography, and histopathologic analysis. Radiology. 2006;239:554-562.
25. Ni Y, Wang H, Chen F, et al. Tumor models and specific contrast agents for small animal imaging in oncology. Methods. 2009;48:125-138.
26. Prise VE, Honess DJ, Stratford MR, et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses. Int J Oncol. 2002;21:717-726.
27. Sun X, Wang H, Chen F, et al. Diffusion-weighted MRI of hepatic tumor in rats: comparison between in vivo and postmortem imaging acquisitions. J Magn Reson Imaging. 2009;29:621-628.
28. Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol. 2009;90:284-294.
29. Yeung SC, She M, Yang H, et al. Combination chemotherapy including combretastatin A4 phosphate and paclitaxel is effective against anaplastic thyroid cancer in a nude mouse xenograft model. J Clin Endocrinol Metab. 2007;92:2902-2909. (Pubitemid 47236348)
30. Koh DM, Padhani AR. Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. Br J Radiol. 2006;79:633-635. (Pubitemid 44283151)
31. Wang H, Sun X, Chen F, et al. Treatment of rodent liver tumor with combretastatin A4 phosphate: noninvasive therapeutic evaluation using multiparametric magnetic resonance imaging in correlation with microangiography and histology. Invest Radiol. 2009;44:44-53.
32. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
33. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421-430. (Pubitemid 32844200)
34. Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002. (Pubitemid 29529292)
35. Arheden H, Saeed M, Higgins CB, et al. Reperfused rat myocardium subjected to various durations of ischemia: estimation of the distribution volume of contrast material with echo-planar MR imaging. Radiology. 2000;215:520-528. (Pubitemid 30237855)
36. Yamada I, Aung W, Himeno Y, et al. Diffusion coefficients in abdominal organs and hepatic lesions: evaluation with intravoxel incoherent motion echo-planar MR imaging. Radiology. 1999;210:617-623. (Pubitemid 29124018)
37. Lang P, Wendland MF, Saeed M, et al. Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging. Radiology. 1998;206:227-235.
38. Bradley DP, Tessier JJ, Ashton SE, et al. Correlation of MRI biomarkers with tumor necrosis in Hras5 tumor xenograft in athymic rats. Neoplasia. 2007;9:382-391. (Pubitemid 46799981)
39. Schima W, Ba-Ssalamah A, Kurtaran A, et al. Post-treatment imaging of liver tumours. Cancer Imaging. 2007;7(spec no A):S28-S36. (Pubitemid 350143144)
40. Ni Y. Metalloporphyrins and Functional Analogues as MRI Contrast Agents. Curr Med Imaging Rev. 2008;4:96-112. (Pubitemid 351890566)
41. Ni Y, Adzamli K, Miao Y, et al. MRI contrast enhancement of necrosis by MP-2269 and gadophrin-2 in a rat model of liver infarction. Invest Radiol. 2001;36:97-103. (Pubitemid 32147856)
42. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn Reson Med. 1991;22:339-342.
43. Idee JM, Port M, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol. 2006;20:563-576. (Pubitemid 44760175)
44. Morcos SK. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol. 2008;66:175-179.
45. Ni Y, Marchal G, Yu J, et al. Localization of metalloporphyrin-induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic, and histologic findings. Acad Radiol. 1995;2:687-699.
46. Kuhl CK, Traber F, Schild HH. Whole-body high-field-strength (3.0-T) MR Imaging in clinical practice. Part I: technical considerations and clinical applications. Radiology. 2008;246:675-696.
47. Dale BM, Braithwaite AC, Boll DT, et al. Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusionweighted imaging of the abdomen. Invest Radiol. 2010;45:104-108.